Gretchen Yandle, MD
Pulmonary Disease · Gonzales, LANPI 1124211099
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 97.0% of the total across 556 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 36 manufacturers, the largest accounting for just 20.3% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $3,285, 2.8 times the $1,181 reported in 2019.
Across 556 payments — averaging $19.57 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$2K
- AstraZeneca$2K
- Actelion Pharmaceuticals US, Inc.$1K
- Boehringer Ingelheim$800
- Sanofi$594
- Insmed, Inc.$400
- plus $4K from 30 others
What the payments were for
- Food & beverage$10,55597%
- Education$3253%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 129 | $2,211 |
| AstraZeneca(2 entities) | 84 | $1,878 |
| Actelion Pharmaceuticals US, Inc. | 74 | $1,290 |
| Boehringer Ingelheim | 48 | $800 |
| Sanofi | 20 | $594 |
| Insmed, Inc. | 25 | $400 |
| Regeneron Healthcare Solutions, Inc. | 9 | $367 |
| Merck | 18 | $342 |
| Mylan Specialty L.p. | 21 | $339 |
| United Therapeutics Corporation | 11 | $264 |
| Amgen | 14 | $237 |
| Genentech USA, Inc. | 14 | $225 |
| Baxter Healthcare | 12 | $219 |
| Mallinckrodt Hospital Products Inc. | 9 | $193 |
| Bayer | 9 | $171 |
| Grifols USA, LLC | 7 | $170 |
| Verona Pharma, Inc. | 9 | $158 |
| Shionogi Inc | 3 | $147 |
| La Jolla Pharmaceutical Company | 1 | $129 |
| Johnson & Johnson(2 entities) | 6 | $93 |
| Electromed, Inc. | 5 | $76 |
| Circassia Inc. | 5 | $74 |
| ERBE USA Inc | 1 | $66 |
| Viatris Specialty LLC | 3 | $65 |
| Abiomed | 1 | $62 |
| Paratek Pharmaceuticals, Inc. | 3 | $57 |
| Advanced Respiratory, Inc | 3 | $54 |
| ANI Pharmaceuticals, Inc. | 2 | $36 |
| Liquidia Technologies, Inc. | 1 | $26 |
| Inogen, Inc. | 1 | $25 |
| Novartis | 2 | $25 |
| CMP Pharma, Inc. | 1 | $21 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $20 |
| Ambu Inc. | 1 | $19 |
| Sunovion Pharmaceuticals Inc. | 2 | $18 |
| Sanofi Pasteur Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$10,879 in reported general payments places this provider in the 70th percentile of 189 pulmonary disease providers in Louisiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 362 | $284,729 |
| AdempasRiociguat | 13 | $173,466 |
| OfevNintedanib Esylate | 11 | $140,675 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 75 | $48,397 |
| Spiriva RespimatTiotropium Bromide | 14 | $8,036 |
| SymbicortBudesonide/Formoterol Fumarate | 16 | $5,964 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 161 | $4,738 |
| Ventolin HfaAlbuterol Sulfate | 28 | $2,087 |
| Nystatin | 18 | $269 |
| Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav | 26 | $227 |
| Prednisone | 23 | $146 |
| Doxycycline Hyclate | 11 | $114 |
| Azithromycin | 16 | $39 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta | $2,211 | $284,729362 claims |
| BayerAdempas | $171 | $173,46613 claims |
| Boehringer IngelheimOfev, Spiriva Respimat | $800 | $148,71125 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $1,878 | $54,36191 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 189 pulmonary disease providers in Louisiana.
Other pulmonary disease in Gonzales
- Bogdan NowakowskiGonzales$12K
- Andrea EspinozaHouma$655K
- Joseph LaskyNew Orleans$447K
- Hollis O NealBaton Rouge$418K
- Ramsy AbdelghaniNew Orleans$308K
- Juzar AliNew Orleans$216K
- Warren BotnickNatchitoches$213K
- Nicole LapinelNew Orleans$140K
- Courtney ShappleyNew Orleans$66K
- Charles GbadouweyMonroe$36K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.